Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158442258> ?p ?o ?g. }
- W2158442258 endingPage "261" @default.
- W2158442258 startingPage "251" @default.
- W2158442258 abstract "Alpha-1 antitrypsin deficiency (AATD) is a rare genetic disease that results from mutations in the alpha-1 antitrypsin (AAT) gene. The mutant AAT protein aggregates and accumulates in the liver leading to AATD liver disease, which is only treatable by liver transplant. The PiZ transgenic mouse strain expresses a human AAT (hAAT) transgene that contains the AATD-associated Glu342Lys mutation. PiZ mice exhibit many AATD symptoms, including AAT protein aggregates, increased hepatocyte death, and liver fibrosis. In the present study, we systemically treated PiZ mice with an antisense oligonucleotide targeted against hAAT (AAT-ASO) and found reductions in circulating levels of AAT and both soluble and aggregated AAT protein in the liver. Furthermore, AAT-ASO administration in these animals stopped liver disease progression after short-term treatment, reversed liver disease after long-term treatment, and prevented liver disease in young animals. Additionally, antisense oligonucleotide treatment markedly decreased liver fibrosis in this mouse model. Administration of AAT-ASO in nonhuman primates led to an approximately 80% reduction in levels of circulating normal AAT, demonstrating potential for this approach in higher species. Antisense oligonucleotides thus represent a promising therapy for AATD liver disease." @default.
- W2158442258 created "2016-06-24" @default.
- W2158442258 creator A5000164054 @default.
- W2158442258 creator A5002817408 @default.
- W2158442258 creator A5004057151 @default.
- W2158442258 creator A5023979875 @default.
- W2158442258 creator A5024156994 @default.
- W2158442258 creator A5027687727 @default.
- W2158442258 creator A5044334898 @default.
- W2158442258 creator A5046724587 @default.
- W2158442258 creator A5072979146 @default.
- W2158442258 creator A5073401519 @default.
- W2158442258 creator A5079060420 @default.
- W2158442258 creator A5079071423 @default.
- W2158442258 date "2013-12-20" @default.
- W2158442258 modified "2023-10-11" @default.
- W2158442258 title "Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin–related liver disease in mice" @default.
- W2158442258 cites W1480615588 @default.
- W2158442258 cites W1484734537 @default.
- W2158442258 cites W1553937011 @default.
- W2158442258 cites W168858771 @default.
- W2158442258 cites W1738068946 @default.
- W2158442258 cites W1900633721 @default.
- W2158442258 cites W1964288182 @default.
- W2158442258 cites W1964727784 @default.
- W2158442258 cites W1968942566 @default.
- W2158442258 cites W1968949098 @default.
- W2158442258 cites W1969602432 @default.
- W2158442258 cites W1970986383 @default.
- W2158442258 cites W1977032724 @default.
- W2158442258 cites W1977373454 @default.
- W2158442258 cites W1977489168 @default.
- W2158442258 cites W1981906938 @default.
- W2158442258 cites W1982406043 @default.
- W2158442258 cites W1984582197 @default.
- W2158442258 cites W1987558289 @default.
- W2158442258 cites W1988684872 @default.
- W2158442258 cites W1998289395 @default.
- W2158442258 cites W1999009890 @default.
- W2158442258 cites W2001042531 @default.
- W2158442258 cites W2004776071 @default.
- W2158442258 cites W2010191137 @default.
- W2158442258 cites W2018349527 @default.
- W2158442258 cites W2031596281 @default.
- W2158442258 cites W2037122026 @default.
- W2158442258 cites W2038041101 @default.
- W2158442258 cites W2045203290 @default.
- W2158442258 cites W2054159211 @default.
- W2158442258 cites W2055653920 @default.
- W2158442258 cites W2057778733 @default.
- W2158442258 cites W2058757351 @default.
- W2158442258 cites W2061092005 @default.
- W2158442258 cites W2061647139 @default.
- W2158442258 cites W2067069944 @default.
- W2158442258 cites W2069070280 @default.
- W2158442258 cites W2075750975 @default.
- W2158442258 cites W2078297752 @default.
- W2158442258 cites W2080606497 @default.
- W2158442258 cites W2080818395 @default.
- W2158442258 cites W2083120544 @default.
- W2158442258 cites W2086500659 @default.
- W2158442258 cites W2089199711 @default.
- W2158442258 cites W2094898345 @default.
- W2158442258 cites W2104564301 @default.
- W2158442258 cites W2123377807 @default.
- W2158442258 cites W2130886644 @default.
- W2158442258 cites W2131810149 @default.
- W2158442258 cites W2140348270 @default.
- W2158442258 cites W2142395184 @default.
- W2158442258 cites W2145007659 @default.
- W2158442258 cites W2148952701 @default.
- W2158442258 cites W2161910349 @default.
- W2158442258 cites W2165209066 @default.
- W2158442258 cites W4210738513 @default.
- W2158442258 cites W4232549932 @default.
- W2158442258 cites W4247981327 @default.
- W2158442258 doi "https://doi.org/10.1172/jci67968" @default.
- W2158442258 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3871221" @default.
- W2158442258 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24355919" @default.
- W2158442258 hasPublicationYear "2013" @default.
- W2158442258 type Work @default.
- W2158442258 sameAs 2158442258 @default.
- W2158442258 citedByCount "68" @default.
- W2158442258 countsByYear W21584422582014 @default.
- W2158442258 countsByYear W21584422582015 @default.
- W2158442258 countsByYear W21584422582016 @default.
- W2158442258 countsByYear W21584422582017 @default.
- W2158442258 countsByYear W21584422582018 @default.
- W2158442258 countsByYear W21584422582019 @default.
- W2158442258 countsByYear W21584422582020 @default.
- W2158442258 countsByYear W21584422582021 @default.
- W2158442258 countsByYear W21584422582022 @default.
- W2158442258 countsByYear W21584422582023 @default.
- W2158442258 crossrefType "journal-article" @default.
- W2158442258 hasAuthorship W2158442258A5000164054 @default.
- W2158442258 hasAuthorship W2158442258A5002817408 @default.
- W2158442258 hasAuthorship W2158442258A5004057151 @default.
- W2158442258 hasAuthorship W2158442258A5023979875 @default.